1. "Early Drug Development Service"
Formats
  1. Meeting Abstract (234)
  2. Journal Article (208)
  3. Review (7)
  4. Editorial (5)
  5. Research Letter (3)
  6. Miscellaneous (2)
  7. Book Section (1)
Groups
  1. Department of Medicine (460)
  2. Early Drug Development Service (460)
  3. Solid Tumor Oncology Division (460)
  4. GSK Faculty (243)
  5. Department of Pathology and Laboratory Medicine (200)
  6. Human Oncology and Pathogenesis Program (193)

More Groups

People
  1. David Hyman (354)
  2. Alison Schram (122)
  3. Alexander Drilon (111)
  4. Michael Berger (111)
  5. David Solit (110)
  6. Marc Ladanyi (91)

More People

Years
  1. 2025 (5)
  2. 2024 (29)
  3. 2023 (18)
  4. 2022 (27)
  5. 2021 (27)
  6. 2020 (49)

More Years

Publications
  1. Journal of Clinical Oncology (111)
  2. Annals of Oncology (38)
  3. Cancer Research (37)
  4. Clinical Cancer Research (33)
  5. Cancer Discovery (22)
  6. Blood (21)

More Publications

Publishers
  1. American Society of Clinical Oncology (126)
  2. American Association for Cancer Research (100)
  3. Oxford University Press (45)
  4. Elsevier Inc. (34)
  5. Nature Publishing Group (29)
  6. American Society of Hematology (23)

More Publishers

Results (460)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Diverse kinase mutations and fusions drive non-Langerhans cell histiocytoses
    Meeting Abstract

    Durham, B.; Diamond, E.; Yao, Z.; Ma, J.; Choi, J.; Kim, E.; Lee, S.; Gao, Y.; Micol, J. B.; Campbell, P.; more...
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • Diffuse loss of cerebral grey matter structures in Erdheim-Chester disease
    Meeting Abstract

    Diamond, E. L.; Hatzoglou, V.; Pandya, S.; Abdel-Wahab, O.; Hyman, D. M.; Rampal, R.; Raj, A.
    Pediatric Blood and Cancer (2015)

    Fulltext@MSK | Save
  • Tumor genetic screening programs: A call to action
    Journal Article

    Hyman, D. M.; Solit, D. B.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Prospective identification of potentially actionable molecular alterations in cancers of unknown primary
    Meeting Abstract

    Varghese, A. M.; Hyman, D. M.; Zehir, A.; Vakiani, E.; Klimstra, D. S.; Ladanyi, M.; Berger, M. F.; Solit, D. B.; Saltz, L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Identifying actionable mutations in uterine leiomyosarcoma
    Meeting Abstract

    Soumerai, T.; Hyman, D. M.; Murali, R.; Zehir, A.; O'Cearbhaill, R. E.; Arcila, M. E.; Aghajanian, C.; Soslow, R. A.; Solit, D. B.; Hensley, M. L.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Tumor relevant germline findings in targeted tumor sequencing using matched normal DNA of 1,570 unselected cases
    Meeting Abstract

    Schrader, K. A.; Cheng, D. T.; Vijai, J.; Prasad, M.; Walsh, M.; Zehir, A.; Thomas, T.; Benayed, R.; Stadler, Z. K.; Ashraf, A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays
    Meeting Abstract

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Nafa, K.; Jour, G.; Razavi, P.; Hyman, D. M.; Baselga, J.; Berger, M. F.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Is next generation sequencing (NGS) ready for routine clinical practice in gliomas? Results of a prospective study utilizing the MSK-IMPACT assay
    Meeting Abstract

    Omuro, A. M. P.; Zehir, A.; Cheng, D. T.; Berger, M. F.; Hyman, D. M.; Solit, D. B.; Baselga, J.; Ladanyi, M.; Arcila, M. E.; Hameed, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Carboplatin hypersensitivity reactions (HSR) in carboplatin retreatment for recurrent ovarian cancer
    Meeting Abstract

    O'Cearbhaill, R. E.; Hyman, D. M.; Tew, W. P.; Iasonos, A.; Cangemi, N. A.; Aghajanian, C.; Bell-Mcguinn, K. M.; Makker, V.; Hensley, M. L.; Konner, J. A.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase I, first-in-human dose study of the dual PI3K/mTOR inhibitor LY3023414 (LY) in patients (pts) with advanced cancer
    Meeting Abstract

    Moore, K. N.; Varghese, A. M.; Hyman, D. M.; Callies, S.; Lin, J.; Wacheck, V.; Pant, S.; Bauer, T. M.; Bendell, J. C.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save